Abstract
Background: Proliferative verrucous leukoplakia (PVL) is a special type of oral leukoplakia with no unified diagnosis criteria. Objective: To evaluate the diagnostic values of NANOG for PVL and explore the associations between NANOG expression and the malignant transformation of PVL. Methods: A total of 112 patients were collected, including 79 cases of PVL (48 cases developed into oral squamous cell carcinoma) and 33 patients diagnosed as conventional oral leukoplakia (COL). The expression of NANOG was detected by immunohistochemical staining. Results: NANOG showed higher expression in 34 cases (70.83%) of PVL with malignant transformation, significantly higher than that in PVL without malignant transformation and COL (P < 0.05). NANOG expression correlated with non-homogeneous clinical manifestation and oral epithelial dysplasia (P < 0.001). ROC analysis revealed its utility in identifying PVL from COL (AUC = 0.674) and predicting malignant transformation (AUC = 0.806, sensitivity 0.900, specificity 0.903). Kaplan-Meier data revealed that patients with high NANOG expression had shorter malignant transformation-free survival (P < 0.001). Multivariate COX analysis confirmed high NANOG expression as an independent risk factor. Conclusions: NANOG is a promising diagnostic and prognostic biomarker for PVL.
Introduction
Oral cancer often begins as leukoplakia—white patches in the mouth. While most are benign, Proliferative Verrucous Leukoplakia (PVL) is a rare, aggressive subtype notorious for recurring and transforming into oral squamous cell carcinoma (OSCC). PVL is a "diagnostic chameleon," often appearing identical to conventional oral leukoplakia (COL) in early stages. Current diagnosis relies on subjective history and oral epithelial dysplasia (OED), yet many PVL cases turn cancerous without showing dysplasia. This study investigates NANOG, a protein associated with stem cell pluripotency, as a potential molecular marker to identify high-risk patients early.
Methods
The researchers conducted a nested case-control study using tissue samples from 112 patients (79 PVL, 33 COL). They employed immunohistochemical (IHC) staining to measure NANOG expression. Statistical tools included ROC analysis for diagnostic accuracy, Kaplan-Meier analysis for transformation-free survival, and Multivariate COX Regression to determine if NANOG is an independent risk factor. Results were validated using an external cohort of 31 patients.
Results
NANOG expression was significantly higher in PVL cases that progressed to cancer compared to non-transforming cases and COL controls.
Key findings include:
- High Correlation: 70.83% of transforming PVL cases showed high NANOG expression.
- Predictive Power: NANOG achieved an AUC of 0.806 for predicting malignant transformation, with high sensitivity (0.900) and specificity (0.903).
- Survival Impact: High NANOG expression was linked to significantly shorter cancer-free survival times (P < 0.001).
- Independent Risk: Multivariate analysis confirmed NANOG as an independent risk factor, providing predictive value beyond age or smoking history.
Discussion
NANOG is a transcription factor that maintains stem cell pluripotency. Its presence in oral lesions suggests cells are reverting to a primitive, "stem-like" state—a hallmark of early cancer development. Interestingly, NANOG levels were high in early PVL stages before cancer appeared but did not change significantly once cancer developed, suggesting it acts as a "trigger" for transformation. Crucially, NANOG outperformed the current gold standard (OED) in predicting cancer, filling a critical gap for PVL cases that lack dysplasia but remain high-risk.
Conclusion
NANOG is a promising diagnostic and prognostic biomarker for PVL. While larger multi-center studies are needed, these results suggest that IHC staining for NANOG could help clinicians identify high-risk lesions earlier and potentially serve as a target for future gene-targeted preventive therapies.
Summary updated